References
- Chowdhury I, Xu W, Stiles JK (2007). Apoptosis of rat granulosa cells after staurosporine and serum withdrawal is suppressed by adenovirus-directed overexpression of prohibitin. Endocrinology, 148, 206-17. https://doi.org/10.1210/en.2006-0187
- Coughlin SS, Ekwueme DU (2009). Breast cancer as a global health concern. Cancer epidemiol, 33, 315-8. https://doi.org/10.1016/j.canep.2009.10.003
- DiRenzo J, Shang Y, Phelan M, et al (2000). BRG-1 is recruited to estrogen-responsive promoters and cooperates with factors involved in histone acetylation. Mol Cell Biol, 20, 7541-9. https://doi.org/10.1128/MCB.20.20.7541-7549.2000
- Dumitrescu RG, Cotarla I (2005), Understanding breast cancer risk - where do we stand in 2005?. J Cell Mol Med, 9, 208-21. https://doi.org/10.1111/j.1582-4934.2005.tb00350.x
- Eveleth DD, Marsh JL (1986). Sequence and expression of Cc gene, a member of dopa decarboxylase gene cluster of Drosophila. Possible translational regulation. Nucleic Acids Res, 14, 6169-83. https://doi.org/10.1093/nar/14.15.6169
- Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008. Int J Cancer, 15, 2893-917.
- Fusaro G, Dasgupta P, Rastogi S, Joshi B, Chellappan S (2003). Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J Biol Chem, 278, 47853-61. https://doi.org/10.1074/jbc.M305171200
- Joshi B, Rastogi S, Morris M (2007). Differential regulation of human YY1 and caspase 7 promoters by prohibitin through E2F1 and p53 binding sites. Biochem J, 401, 155-66. https://doi.org/10.1042/BJ20060364
- Julian Peto, Nadine Collins, Rita Barfoot, et al (1999). Prevalence of BRCA1 and BRCA2 Gene Mutation in Patients with Early-Onset Of Breast Cancer. J Natl Cancer Inst, 91, 943-9. https://doi.org/10.1093/jnci/91.11.943
- Kuusisto KM, Bebel A, Vihinen M, et al (2011). Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res, 13, R20. https://doi.org/10.1186/bcr2832
- Maillet P, Bonnefoi H, Vaudan-Vutskits G, et al (2002). Constitutional alteration of the ATM gene in early onset sporadic breast cancer. J Med Genet, 39, 751-3. https://doi.org/10.1136/jmg.39.10.751
- Manjeshwar S, Branam DE, Lerner MR, Brackett DJ, Jupe ER, et al (2003). Tumor suppression by the prohibitin gene 3´ untranslated region RNA in human breast cancer. Cancer Res. 63, 5251-6
- McKean-Cowdin R, Kolonel LN, Press MF, Pike MC, Henderson BE (2001). Germ-line HER-2 Variant and Breast Cancer Risk by Stage of Disease. Cancer Res, 61, 8393-4.
- Nagai MA, Yamamoto L, Salaorni S, et al (1994). Detailed deletion mapping of chromosome segment 17q12-21 in sporadic breast tumors. Genes Chromosomes Cancer, 11, 58-62. https://doi.org/10.1002/gcc.2870110109
- Nuell MJ, Stewart DA, Walker L, et al (1991). Prohibitin, an evolutionarily conserved intracellular protein that blocks DNA synthesis in normal fibroblasts and HeLa cells. Mol Cell Biol, 11, 1372-81.
- Rajalingam K, Rudel T (2005). Ras-Raf signaling needs prohibitin. Cell Cycle, 4, 1503-5. https://doi.org/10.4161/cc.4.11.2142
- Saeki T, Tsuruo T, Sato W, Nishikawsa K (2005). Drug resistance in chemotherapy for breast cancer. Cancer Chemother Pharmacol, 56, 84-9. https://doi.org/10.1007/s00280-005-0106-4
- Sato T, Saito H, Swensen J, et al (1992). The human prohibitin gene located on chromosome 17q21 is mutated in sporadic breast cancer. Cancer Res, 52, 1643-6.
- Sato T, Sakamoto T, Takita K, et al (1993). The human prohibitin (PHB) gene family and its somatic mutations in human tumors. Genomics, 17, 762-4. https://doi.org/10.1006/geno.1993.1402
- Snedden WA, Fromm H (1997). Characterization of the plant homologue of prohibitin, a gene associated with antiproliferative activity in mammalian cells. Plant Mol Biol, 33, 753-6. https://doi.org/10.1023/A:1005737026289
- Vargo-Gogola T, Rosen JM (2007). Modelling breast cancer: one size does not fit all. Nat Rev Cancer, 7, 659-72. https://doi.org/10.1038/nrc2193
- Wang S, Zhang B, Faller DV (2004). BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists. EMBO J, 23, 2293-303. https://doi.org/10.1038/sj.emboj.7600231
- Wang S, Nath N, Adlam M, Chellappan S (1999a). Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function. Oncogene, 18, 3501-10. https://doi.org/10.1038/sj.onc.1202684
- Wang S, Nath N, Fusaro G, Chellappan S (1999b). Rb and prohibitin target distinct regions of E2F1 for repression and respond to different upstream signals. Mol Cell Biol, 19, 7447-60.
- Zhang B, Chambers KJ, Faller DV, Wang S (2007). Reprogramming of the SWI/SNF complex for co-activation or co-repression in prohibitin-mediated estrogen receptor regulation. Oncogene, 26, 7153-7. https://doi.org/10.1038/sj.onc.1210509
Cited by
- Immunohistochemical expression and mutation study of Prohibitin gene in Indian female breast cancer cases vol.30, pp.3, 2013, https://doi.org/10.1007/s12032-013-0614-8
- A novel spiroindoline targets cell cycle and migration via modulation of microtubule cytoskeleton vol.429, pp.1-2, 2017, https://doi.org/10.1007/s11010-016-2932-6
- Genetic determinants of sporadic breast cancer in Sri Lankan women vol.18, pp.1, 2018, https://doi.org/10.1186/s12885-018-4112-4